Use of cotinine in treating psychiatric disorders
July 30, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3870794 Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method Method for treatment of neurodegenerative diseases Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine Use of cotinine to assist in the cessation of tobacco smoking Human body weight management Patent #: 5643928 InventorAssigneeApplicationNo. 688363 filed on 07/30/1996US Classes:514/343, The additional hetero ring consists of one nitrogen and four carbons (e.g., nicotine, etc.)514/327Chalcogen bonded directly to ring carbon of the piperidine ringExaminersPrimary: Spivack, Phyllis G.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/44A61K 031/445 AbstractA pharmaceutical composition is provided that is useful in treating obsessive-compulsive disorder, Tourette's Syndrome and schizophrenia comprising an amount of cotinine or a pharmaceutically acceptable salt thereof, which amount is effective to reduce or alleviate at least one of the symptoms of Tourette's Syndrome, obsessive-compulsive disorder, or schizophrenia in a human or other mammal.Other References
| |
